Skip to main content

axitinib

Generic: AXITINIB·Brand: AXITINIB, INLYTA, Inlyta

axitinib: 7 clinical trials tracked.

axitinib evidence translation

What we can confirm

7 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about axitinib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 4 study sponsors
Clinical Trials (7)

Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]

NCT07383441·Phase 3
Recruiting

Primary endpoint: Progression-free survival (PFS)

InterventionalRandomizeddouble718 targetStarted 2026-06Completion 2034-0141 sites · United StatesSWOG Cancer Research Network

A Phase 1/2 Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

NCT05949632·Phase 1/Phase 2·INCY
Terminated

Primary endpoint: Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)

Interventionalopen5 targetStarted 2024-04Completion 2025-066 sites · United KingdomIncyte Corporation

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

NCT05327686·Phase 2·CGON
Recruiting

Primary endpoint: Nephrectomy and radiographic progression-free survival (nrPFS)

InterventionalRandomizedopen240 targetStarted 2023-02Completion 2033-0650 sites · United StatesNRG Oncology

AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED AVELUMAB CLINICAL STUDIES.

NCT05059522·Phase 3·PFE
Active, not recruiting

Primary endpoint: Number of participants with adverse events leading to permanent discontinuation of study intervention

Interventionalopen77 targetStarted 2021-09Completion 2026-1250 sites · Australia, Belgium, Canada, Denmark…Pfizer

Phase 2 Study of Axitinib + Ipilimumab in Advanced Melanoma

NCT04996823·Phase 2·GHRS
Active, not recruiting

Primary endpoint: Overall Response Rate

Interventionalopen24 targetStarted 2021-08Completion 2027-031 site · United StatesH. Lee Moffitt Cancer Center and Research Institute

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial

NCT03297606·Phase 2
Recruiting

Primary endpoint: Objective response rate defined as the number of patients with complete response or partial response

Interventionalopen720 targetStarted 2018-03Completion 2027-0110 sites · CanadaCanadian Cancer Trials Group

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

NCT02925234·Phase 2
Recruiting

Primary endpoint: Percentage of patients that are treated based on their molecular tumor profile

Interventionalopen1,550 targetStarted 2016-08Completion 2027-1236 sites · NetherlandsThe Netherlands Cancer Institute